Mariner
ARQT icon

Mariner’s Arcutis Biotherapeutics ARQT Stock Holding History

Mariner’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$560K Sell
23,774
-2,497
-10% -$63.7K ﹤0.01% 2406
2025
Q4 		$762K Buy
26,271
+10,805
+70% +$277K ﹤0.01% 2141
2025
Q3 		$292K Buy
15,466
+5,123
+50% +$80.8K ﹤0.01% 2837
2025
Q2 		$145K Buy
+10,343
New +$145K ﹤0.01% 3156
2025
Q1 		– Sell
-10,028
Closed -$140K – 3444
2024
Q4 		$140K Sell
10,028
-180
-2% -$1.97K ﹤0.01% 3106
2024
Q3 		$94.9K Sell
10,208
-518
-5% -$5.11K ﹤0.01% 3101
2024
Q2 		$99.8K Sell
10,726
-7,079
-40% -$64K ﹤0.01% 2956
2024
Q1 		$176K Buy
+17,805
New +$133K ﹤0.01% 2804

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return